Lineage Cell Therapeutics (LCTX) Operating Expenses (2010 - 2026)

Lineage Cell Therapeutics' Operating Expenses history runs 17 years deep, the most recent figure standing at $9.3 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 16.37% year-over-year to $9.3 million; the TTM figure through Mar 2026 stood at $52.5 million (up 69.97% YoY), while the FY2025 annual figure was $51.2 million, up 65.2% from the prior year.
• Operating Expenses for Q1 2026 stood at $9.3 million, down from $13.2 million in the prior quarter.
• The five-year high for Operating Expenses was $22.5 million in Q2 2025, with the low at $7.3 million in Q2 2024.
• The 5-year median for Operating Expenses is $8.2 million (2023), against an average of $9.5 million.
• The sharpest annual moves came in 2022 and 2025: Operating Expenses tumbled 71.06% in 2022, then jumped 209.9% in 2025.
• Lineage Cell Therapeutics' Operating Expenses stood at $8.5 million in 2022, then dropped by 3.05% to $8.2 million in 2023, then retreated by 2.64% to $8.0 million in 2024, then soared by 64.9% to $13.2 million in 2025, then declined by 29.17% to $9.3 million in 2026.
• Business Quant data shows LCTX's Operating Expenses at $9.3 million in Q1 2026, $13.2 million in Q4 2025, and $7.5 million in Q3 2025.